Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Amino acid sequence disclosed in whole or in part; or...
Reexamination Certificate
2008-03-25
2008-03-25
Haddad, Maher M. (Department: 1644)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Amino acid sequence disclosed in whole or in part; or...
C514S002600, C530S350000
Reexamination Certificate
active
09554860
ABSTRACT:
The present invention provides a novel treatment for allergy comprising a recombinant allergen with reduced enzymatic activity, thereby reducing the potential for an allergic response upon contact with a wild-type allergen.
REFERENCES:
patent: 5762943 (1998-06-01), Dolovich et al.
patent: 6287559 (2001-09-01), King
patent: WO 94/05790 (1994-03-01), None
patent: 97/07218 (1997-02-01), None
Topham et al. (Protein Engineering 1994; 7(7): 869-894.
Smith et al. (Molecular Immunology 1996; 33(4/5): 399-405).
Robinson et al., Clinical and Experimental Allergy, 1997, vol. 27, pp. 10-21.
Forster et al., Journal of Allergy and Clinical Immunology, 1995, vol. 95, pp. 1229-1235.
Creighton, T.E. ‘Proteins Structures and Molecular Properties.’ W.H. Freeman and Company: New York, 1993. pp. 79-81.
Topham, et al., “Comparative Modelling of Major House Dust Mite AllergenDer pI: Structure Validation Using an Extended Environmental Amino Acid Propensity Table”,Protein Engineering, 7(7): 869-894 (1994).
Hewitt, et al., “Heterogeneous Proteolytic Specificity and Activity of the House Dust Mite Proteinase AllergenDer pI”,Clinical and Experimental Allergy, 27: 201-207 (1997).
Hewitt, et al., “A Major House Dust Mite Allergen Disrupts the Immunoglobulin E Network by Selectively Cleaving CD23: Innate Protection by Antiproteases”,J. Exp. Med., 182: 1537-1544 (1995).
Chua, et al., International Arch Allergy Immunol., vol. 101 pp. 364-368 (1993).
NCBI Accession No. P08176(DerP1) 9 pages.
Robinson, et al.,Clinical ad Experimental Allergy, vol. 27 pp. 10-21 (1997).
Barrett, et al.,Handbook of Proteolytic Enzymes, Ch. 186 pp. 546-555 Oct. 13, 1998.
Groves, et al.,Structure, vol. 4 pp. 1193-1203 (1996).
Chua, et al.,J. Exp. Med., vol. 167 pp. 175-182 (1988).
Schultz, et al.,J. Exp. Med., vol. 187(2) pp. 271-275 (1998).
Carmona, et al.,Biochemistry, vol. 35 pp. 8149-8157 (1996).
Jahn-Schmid, et al.,Immunotechnology, vol. 2 pp. 103-113 (1996).
Bollen Alex
Bruck Claudine
Jacobs Paul
Massaer Marc Georges Francis
Fedon Jason C.
Gimmi Edward R.
Haddad Maher M.
Rooney Nora M.
SmithKline Beecham Biologicals (s.a.)
LandOfFree
Recombinant allergen with reduced enzymatic activity does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Recombinant allergen with reduced enzymatic activity, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Recombinant allergen with reduced enzymatic activity will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3928130